Bayer AG BAYN

WHIPPANY, N.J., October 01, 2026--Alka-Seltzer Plus® will relaunch in 2026 as Alka-Seltzer™ Cold, introducing a more intuitive brand architecture, simplified packaging and value-focused options designed to make the cough/cold aisle easier to shop. The relaunch reflects a sharper focus on the moments when consumers are sick, pressed for time and looking for trusted solutions that are easy to understand and accessible at the shelf.

Bayer has delivered a sharp share price recovery over the past year, which puts fresh attention on a simple question about the stock: Are investors now paying a price that still lines up with what the business generates in sales? Bayer’s 83.8% 1 year return puts a lot of recent optimism on trial against what the company’s revenue base can realistically support. New U.S. regulatory milestones for therapies like Lynkuet for vasomotor symptoms in breast cancer patients and KERENDIA for chronic...